Clinical trials: Renal Transplant Recipient
Organ Donor, Brain Death
Therapeutic Hypothermia in "Expanded Criteria" Brain-dead Donors and Kidney-graft Function
Each year, only one third of patients registered on the waiting list receive a kidney transplant. Numerous paths are being explored with the aim of reversing this shortage.
- Conditions
- Organ Donor, Brain Death, Kidney Transplant; Complications, Critical Illness
- Trial name
- HYPOREME (NCT03098706)
- Testing
- Procedure control: normothermia, Procedure active
- Where
- 54 sites in France
- Volunteers
- 532 people
- Sponsor
- Nantes University Hospital
Kidney Transplantation Recipients
Assessment of CMV-specific ELISPOT Assay for Predicting CMV Infection in Kidney Transplant Recipients
CMV is one of the most important opportunistic infection in transplant recipients. In South Korea, more than 95% of adults reveal sero-positivity for CMV IgG.
- Trial name
- ACE-KT (NCT02025335)
- Where
- South Korea
- Volunteers
- 199 people
- Sponsor
- Asan Medical Center
Kidney Transplantation
Testing the Effect of KnowMAP (Knowledge Management for Renal Transplant Recipients). A Randomized Controlled Study
A randomized controlled study (RCT) aiming to test the effect of a new health literacy intervention for renal transplant recipients, KnowMAP (knowledge management for renal transplant recipients).
- Trial name
- KnowMAP (NCT04296955)
- Testing
- Motivational interview as a new health communication intervention
- Where
- Norway
- Volunteers
- 200 people
- Sponsor
- Oslo University Hospital
COVID-19 Vaccines, Varicella Zoster Vaccine
PREPARE-iVAC Trial
Objective: To investigate whether replacement of MMF/MPA by everolimus in kidney transplant recipients results in superior immunogenicity of COVID-19 vaccination as measured by neutralizing antibody titer against the Omicron…
- Conditions
- COVID-19 Vaccines, Varicella Zoster Vaccine, Vaccine Response, Immunosuppression
- Trial name
- PREPARE-iVAC (NCT05924685)
- Testing
- COVID-19 vaccination
- Where
- 7 sites in Netherlands
- Volunteers
- 110 people
- Sponsor
- University Medical Center Groningen
Kidney Transplantation
Everolimus in Combination With Cyclosporine Microemulsion in de Novo Renal Transplant Recipients
The purpose of the study in de novo renal transplant patients is to evaluate the effect on renal function of an optimized new regimen in comparison with the standard everolimus exposure plus a low-dose cyclosporine microemulsion…
- Trial name
- NCT00170885
- Testing
- Everolimus
- Where
- Switzerland
- Sponsor
- Novartis
Hyperlipidemias
Lipid Management in Renal Transplant Recipients Using Evolocumab.
Cardiovascular disease is the leading cause of mortality after renal transplantation, accounting for more than 30% of deaths. Elevated lipid levels (hyperlipidemia) are a frequent finding following transplantation and the…
- Trial name
- NCT04608474
- Testing
- Evolocumab
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- Brigham and Women's Hospital
Renal Anemia
Variability of Hemoglobin Levels After Kidney Transplantation
The purpose of this study es to determine hemoglobin variability in kidney transplant recipients with chronic renal anemia.
- Trial name
- NCT02041208
- Testing
- kidney transplantation
- Where
- 22 sites in Spain
- Volunteers
- 368 people
- Sponsor
- Sociedad Española de Trasplante
Transplant Dysfunction, Magnesium Disorder
Effects of Proton Pump Inhibitors on Kidney Transplant Recipients
Use of proton pump inhibitors (PPIs) is quite common among renal transplant recipients and reduced kidney functions and hypomagnesemia with the use of PPIs have been reported.
- Trial name
- NCT03123796
- Where
- Turkey (Türkiye)
- Volunteers
- 300 people
- Sponsor
- Istanbul University
Renal Failure, Chronic, Renal Transplantation
Immunoregulatory Effects of Immunoglobulin Induction Therapy in Renal Transplant Recipients
The aim of this randomized prospective study in renal transplant recipients is to investigate immunological short and long-term effects of an IVIG induction therapy.
- Trial name
- NCT00176059
- Testing
- intravenous immunoglobulins (IVIG), kidney transplantation
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- University of Giessen
End-Stage Renal Disease
Study on the Safety and Efficacy of a Time-of-Day-Based Individualized Tacrolimus Dosing Regimen in Kidney Transplant Recipients
The goal of this clinical trial is to evaluate whether chronopharmacokinetic model-guided individualized unequal twice-daily tacrolimus dosing improves renal allograft function and reduces acute rejection in stable kidney…
- Trial name
- NCT07877103
- Testing
- Chronotherapy-based individualized low-morning high-evening tacrolimus dosing, conventional dosing regimen
- Where
- China
- Volunteers
- 100 people
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
Kidney Transplantation
Combination Drug Therapy Followed by Single Drug Steroid Free Therapy to Prevent Organ Rejection in Kidney Transplantation
This study will test the safety and effectiveness of a combination of three drugs followed by long-term treatment with just one drug in preventing organ rejection in kidney transplant patients.
- Trial name
- NCT00076570
- Testing
- Sirolimus, Tacrolimus
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Kidney Transplantation
Information and Communication Technology (ICT) Based Centralized Clinical Trial Monitoring System for Drug Adherence
Immunosuppression non-adherence in kidney transplant recipients (KTRs) not only increases the risk of medical intervention due to acute rejection and graft loss but burdens the socioeconomic system in the form of increased…
- Trial name
- NCT03136588
- Testing
- Feedback using ICT based monitoring system
- Where
- 2 sites in South Korea
- Volunteers
- 114 people
- Sponsor
- Kyungpook National University Hospital
Liver Transplant
A Multicentre, Randomised, Open-label, Controlled, 12-month Follow-up Study to Assess Impact on Renal Function of an Immunosuppression Regimen Based on Tacrolimus Minimisation in Association With Everolimus in de Novo Liver Transplant Recipients.
Assuming greater efficacy in the prevention of acute rejection in the EVR arm with minimisation of TAC levels, the hypothesis of the present trial was that the introduction of EVR in combination with the minimisation of TAC…
- Trial name
- REDUCE (NCT02040584)
- Testing
- Minimisation of TAC, TAC + MMF + corticosteroids
- Where
- 20 sites in Spain
- Volunteers
- 217 people
- Sponsor
- Novartis Pharmaceuticals
Renal Transplant Recipients
Efficacy and Safety Study of the Switch From Cyclosporin to Tacrolimus in Renal Transplant Recipients
The objective of this study is to evaluate the effects of tacrolimus sustained-release capsules replacing cyclosporin on kidney function of renal transplant recipients.
- Trial name
- NCT02706678
- Testing
- Tacrolimus sustained-release capsule
- Where
- 9 sites in China
- Volunteers
- 105 people
- Sponsor
- Astellas Pharma China, Inc.
Transplant Rejection
BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR)
Primary Objectives: Cohort A: To evaluate the efficacy of BIVV020 in prevention of AMR Cohort B: To evaluate the efficacy of BIVV020 in treatment of active AMR Secondary Objectives: To assess the overall efficacy of BIVV020 in…
- Trial name
- NCT05156710
- Testing
- BIVV020 (SAR445088), Intravenous immunoglobulin (IVIg), Rituximab or biosimilar
- Where
- 27 sites in United States, Canada and 5 more
- Volunteers
- 48 people
- Sponsor
- Sanofi
Renal Failure
Preemptive Treatment With Grazoprevir and Elbasvir for Donor HCV Positive to Recipient HCV Negative Kidney Transplant
Proof of concept, open-label single center study for the donation of HCV positive kidneys to HCV negative patients, with preemptive, interventional treatment to prevent HCV transmission upon transplantation.
- Trial name
- NCT02945150
- Testing
- elbasvir (50mg) / grazoprevir (100mg) (fixed dose combination)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Massachusetts General Hospital
Transplant Recipient (Kidney), Primary Kidney Transplantation
Posttranslationally Modified Fetuin-A in Urine as a Marker for Renal Dysfunction (Patients With Chronic Kidney Disease - With or Without Kidney Transplantation).
Kidney transplantation is the preferred treatment method for patients with chronic kidney disease. Standard parameters (estimated glomerular filtration, albuminuria) of renal function detection are limited by many factors…
- Trial name
- (uPTM-FetA) (NCT06950931)
- Testing
- uPTM-FeA
- Where
- Slovakia
- Volunteers
- 86 people
- Sponsor
- University Hospital, Martin
Kidney Transplant; Complications
Esomeprazole or Pantoprazole in Renal Transplantation
prospective, parallel, open-label clinical trial was performed on forty-seven adult renal transplant recipients receiving immunosuppressive therapy with CsA doses adjusted to attain trough concentrations of 100-150 μg/L…
- Trial name
- NCT03812419
- Testing
- Esomeprazole 40 mg, Pantoprazole 40mg
- Volunteers
- 47 people
- Sponsor
- Future University in Egypt
End Stage Renal Disease
Trial to Evaluate Safety and Tolerability of Tacrolimus Extended-Release (Astagraf XL) in Human Leukocyte Antigen (HLA) Sensitized Kidney Transplant Recipients
The purpose of this study is to demonstrate the safety of tacrolimus extended-release in HLA sensitized (HS, defined as panel reactive antibody ≥ 30%), kidney transplant recipients after desensitization with intravenous…
- Trial name
- NCT03194321
- Testing
- Tacrolimus Extended-Release Oral Capsule
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Cedars-Sinai Medical Center
Kidney Transplant Rejection, End Stage Renal Disease
Safety & Tolerability Study of Chimeric Antigen Receptor T-Reg Cell Therapy in Living Donor Renal Transplant Recipients
The purpose of this study is to evaluate the safety and tolerability of TX200-TR101 and its effects on the donated kidney in living donor kidney transplant recipients.
- Trial name
- STEADFAST (NCT04817774)
- Testing
- TX200-TR101
- Where
- 5 sites in Belgium, Netherlands and 1 more
- Volunteers
- 26 people
- Sponsor
- Sangamo Therapeutics